Skip to main content
KYTX
NASDAQ Life Sciences

Kyverna Posts Q3 Loss of $41.9M, Ends Quarter With $170.6M and BLA Filed for Miv-cel

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.2
Mkt Cap
$316.638M
52W Low
$4.495
52W High
$13.67
52W Position info
16% above low
Off High info
62% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KYTX sits 16% above its 52-week low of $4.495.

Summary

Kyverna's Q3 8-K furnishes results showing a $41.9M net loss and $170.6M in cash — runway into 2028 — alongside the already-announced completion of its miv-cel BLA in stiff person syndrome with a priority-review request.


Key Events · Earnings and Guidance · KYTX

  • Miv-cel BLA Submitted for Priority Review

    Kyverna completed its rolling BLA for miv-cel in stiff person syndrome and requested priority review under its RMAT designation; FDA acceptance and the review decision are not yet disclosed.

  • Q3 Net Loss of $41.9M

    Net loss was $41.9M, or $0.68 per share, on R&D of $27.0M and G&A of $15.9M; G&A rose from $8.3M a year earlier as commercial readiness spending began.

  • Cash of $170.6M, Runway Into 2028

    Cash, equivalents and marketable securities totaled $170.6M at September 30, 2026, down from $279.3M at year-end 2025; management expects this plus the Oxford Finance facility to fund operations into 2028.

  • KYV-102 Program Deprioritized

    Kyverna is dropping focus on KYV-102 to concentrate resources on late-stage miv-cel neurologic indications.


Analysis · KYTX · Life Sciences

The headline event — completion of the rolling BLA for miv-cel in stiff person syndrome with a priority-review request — was already out via the same-day press release, so the incremental news here is the financial detail. Kyverna burned $41.9M in the quarter and ended September with $170.6M in cash and securities, which management says funds operations into 2028; that runway covers the anticipated 2027 launch window but leaves little cushion if the FDA slows the review or demands more data. G&A jumped to $15.9M from $8.3M a year ago as commercial build-out begins, while R&D fell to $27.0M from $30.5M. The company also shelved KYV-102 to concentrate spending on miv-cel, a sign of capital discipline rather than distress. The binary risk remains FDA acceptance and priority-review grant, neither of which is confirmed in this filing.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KYTX was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $316.6M. The 52-week trading range was $4.50 to $13.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KYTX - Latest Insights

KYTX
Nov 12, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.20
Real-time Price: $5.84 info
Change: +$0.640 (+12%) info
Market Cap: $316.638M info
KYTX
Oct 23, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $5.84 info
Change: +$0.410 (+8%) info
Market Cap: $316.638M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.05
Real-time Price: $5.84 info
Change: -$1.21 (-17%) info
Market Cap: $316.638M info
KYTX
Sep 24, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $7.19
Real-time Price: $5.84 info
Change: -$1.35 (-19%) info
Market Cap: $316.638M info
KYTX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.02
Real-time Price: $5.84 info
Change: -$2.18 (-27%) info
Market Cap: $316.638M info